Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer

The Influence of Age, Grade, and Histological Type

William D. Foulkes, Kelly Metcalfe, Ping Sun, Wedad M. Hanna, Henry T. Lynch, Parviz Ghadirian, Nadine Tung, Olufunmilayo I. Olopade, Barbara L. Weber, Jane McLennan, Ivo A. Olivotto, Louis R. Bégin, Steven A. Narod

Research output: Contribution to journalArticle

207 Citations (Scopus)

Abstract

Purpose: BRCA1-related breast cancers are more frequently estrogen receptor (ER) negative than are either BRCA2-related or nonhereditary breast cancers. The relationship between ER status and other clinical features of hereditary breast cancers has not been well studied. Experimental Design: ER status, grade, and histological tumor type were evaluated in 1131 women with invasive breast cancer, ascertained at 10 centers in North America. There were 208 BRCA1 mutation carriers, 88 BRCA2 carriers, and 804 women without a known mutation. We stratified the patients by mutation status, grade, age, and histological type and calculated the percentage of ER-positive tumors within each stratum. Results: BRCA1 mutation carriers were more likely to have ER-negative breast cancers than were women in other groups, after adjustment for age, grade, and histological subtype (P <0.001). Only 3.9% of BRCA1-related breast cancers were ER-positive cancers occurring in women in their postmenopausal years. The direction and magnitude of the change in ER status with increasing age at diagnosis in BRCA1 carriers was significantly different from in BRCA2 carriers (Pintercept = 0.0002, P slope = 0.04). Notably, changes in ER status with age at diagnosis for BRCA1 carriers and noncarriers were almost identical (Pslope = 0.98). Conclusions: The strong relationship between the presence of a BRCA1 mutation and the ER-negative status of the breast cancers is neither a consequence of the young age at onset nor the high grade but is an intrinsic property of BRCA1-related cancers. The ER-negative status of these cancers may reflect the cell of origin of BRCA1-related cancers.

Original languageEnglish
Pages (from-to)2029-2034
Number of pages6
JournalClinical Cancer Research
Volume10
Issue number6
DOIs
StatePublished - Mar 15 2004

Fingerprint

Estrogen Receptors
Breast Neoplasms
Mutation
Neoplasms
North America
Age of Onset
Research Design

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer : The Influence of Age, Grade, and Histological Type. / Foulkes, William D.; Metcalfe, Kelly; Sun, Ping; Hanna, Wedad M.; Lynch, Henry T.; Ghadirian, Parviz; Tung, Nadine; Olopade, Olufunmilayo I.; Weber, Barbara L.; McLennan, Jane; Olivotto, Ivo A.; Bégin, Louis R.; Narod, Steven A.

In: Clinical Cancer Research, Vol. 10, No. 6, 15.03.2004, p. 2029-2034.

Research output: Contribution to journalArticle

Foulkes, WD, Metcalfe, K, Sun, P, Hanna, WM, Lynch, HT, Ghadirian, P, Tung, N, Olopade, OI, Weber, BL, McLennan, J, Olivotto, IA, Bégin, LR & Narod, SA 2004, 'Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer: The Influence of Age, Grade, and Histological Type', Clinical Cancer Research, vol. 10, no. 6, pp. 2029-2034. https://doi.org/10.1158/1078-0432.CCR-03-1061
Foulkes, William D. ; Metcalfe, Kelly ; Sun, Ping ; Hanna, Wedad M. ; Lynch, Henry T. ; Ghadirian, Parviz ; Tung, Nadine ; Olopade, Olufunmilayo I. ; Weber, Barbara L. ; McLennan, Jane ; Olivotto, Ivo A. ; Bégin, Louis R. ; Narod, Steven A. / Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer : The Influence of Age, Grade, and Histological Type. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 6. pp. 2029-2034.
@article{a095da9cf7b54a16aca8719b2b2e9784,
title = "Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer: The Influence of Age, Grade, and Histological Type",
abstract = "Purpose: BRCA1-related breast cancers are more frequently estrogen receptor (ER) negative than are either BRCA2-related or nonhereditary breast cancers. The relationship between ER status and other clinical features of hereditary breast cancers has not been well studied. Experimental Design: ER status, grade, and histological tumor type were evaluated in 1131 women with invasive breast cancer, ascertained at 10 centers in North America. There were 208 BRCA1 mutation carriers, 88 BRCA2 carriers, and 804 women without a known mutation. We stratified the patients by mutation status, grade, age, and histological type and calculated the percentage of ER-positive tumors within each stratum. Results: BRCA1 mutation carriers were more likely to have ER-negative breast cancers than were women in other groups, after adjustment for age, grade, and histological subtype (P <0.001). Only 3.9{\%} of BRCA1-related breast cancers were ER-positive cancers occurring in women in their postmenopausal years. The direction and magnitude of the change in ER status with increasing age at diagnosis in BRCA1 carriers was significantly different from in BRCA2 carriers (Pintercept = 0.0002, P slope = 0.04). Notably, changes in ER status with age at diagnosis for BRCA1 carriers and noncarriers were almost identical (Pslope = 0.98). Conclusions: The strong relationship between the presence of a BRCA1 mutation and the ER-negative status of the breast cancers is neither a consequence of the young age at onset nor the high grade but is an intrinsic property of BRCA1-related cancers. The ER-negative status of these cancers may reflect the cell of origin of BRCA1-related cancers.",
author = "Foulkes, {William D.} and Kelly Metcalfe and Ping Sun and Hanna, {Wedad M.} and Lynch, {Henry T.} and Parviz Ghadirian and Nadine Tung and Olopade, {Olufunmilayo I.} and Weber, {Barbara L.} and Jane McLennan and Olivotto, {Ivo A.} and B{\'e}gin, {Louis R.} and Narod, {Steven A.}",
year = "2004",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-03-1061",
language = "English",
volume = "10",
pages = "2029--2034",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer

T2 - The Influence of Age, Grade, and Histological Type

AU - Foulkes, William D.

AU - Metcalfe, Kelly

AU - Sun, Ping

AU - Hanna, Wedad M.

AU - Lynch, Henry T.

AU - Ghadirian, Parviz

AU - Tung, Nadine

AU - Olopade, Olufunmilayo I.

AU - Weber, Barbara L.

AU - McLennan, Jane

AU - Olivotto, Ivo A.

AU - Bégin, Louis R.

AU - Narod, Steven A.

PY - 2004/3/15

Y1 - 2004/3/15

N2 - Purpose: BRCA1-related breast cancers are more frequently estrogen receptor (ER) negative than are either BRCA2-related or nonhereditary breast cancers. The relationship between ER status and other clinical features of hereditary breast cancers has not been well studied. Experimental Design: ER status, grade, and histological tumor type were evaluated in 1131 women with invasive breast cancer, ascertained at 10 centers in North America. There were 208 BRCA1 mutation carriers, 88 BRCA2 carriers, and 804 women without a known mutation. We stratified the patients by mutation status, grade, age, and histological type and calculated the percentage of ER-positive tumors within each stratum. Results: BRCA1 mutation carriers were more likely to have ER-negative breast cancers than were women in other groups, after adjustment for age, grade, and histological subtype (P <0.001). Only 3.9% of BRCA1-related breast cancers were ER-positive cancers occurring in women in their postmenopausal years. The direction and magnitude of the change in ER status with increasing age at diagnosis in BRCA1 carriers was significantly different from in BRCA2 carriers (Pintercept = 0.0002, P slope = 0.04). Notably, changes in ER status with age at diagnosis for BRCA1 carriers and noncarriers were almost identical (Pslope = 0.98). Conclusions: The strong relationship between the presence of a BRCA1 mutation and the ER-negative status of the breast cancers is neither a consequence of the young age at onset nor the high grade but is an intrinsic property of BRCA1-related cancers. The ER-negative status of these cancers may reflect the cell of origin of BRCA1-related cancers.

AB - Purpose: BRCA1-related breast cancers are more frequently estrogen receptor (ER) negative than are either BRCA2-related or nonhereditary breast cancers. The relationship between ER status and other clinical features of hereditary breast cancers has not been well studied. Experimental Design: ER status, grade, and histological tumor type were evaluated in 1131 women with invasive breast cancer, ascertained at 10 centers in North America. There were 208 BRCA1 mutation carriers, 88 BRCA2 carriers, and 804 women without a known mutation. We stratified the patients by mutation status, grade, age, and histological type and calculated the percentage of ER-positive tumors within each stratum. Results: BRCA1 mutation carriers were more likely to have ER-negative breast cancers than were women in other groups, after adjustment for age, grade, and histological subtype (P <0.001). Only 3.9% of BRCA1-related breast cancers were ER-positive cancers occurring in women in their postmenopausal years. The direction and magnitude of the change in ER status with increasing age at diagnosis in BRCA1 carriers was significantly different from in BRCA2 carriers (Pintercept = 0.0002, P slope = 0.04). Notably, changes in ER status with age at diagnosis for BRCA1 carriers and noncarriers were almost identical (Pslope = 0.98). Conclusions: The strong relationship between the presence of a BRCA1 mutation and the ER-negative status of the breast cancers is neither a consequence of the young age at onset nor the high grade but is an intrinsic property of BRCA1-related cancers. The ER-negative status of these cancers may reflect the cell of origin of BRCA1-related cancers.

UR - http://www.scopus.com/inward/record.url?scp=12144290945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144290945&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-03-1061

DO - 10.1158/1078-0432.CCR-03-1061

M3 - Article

VL - 10

SP - 2029

EP - 2034

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -